PRISM Psychedelics Watchlist: Sector Momentum Builds in 2026

The PRISM Psychedelics Index delivered the strongest move across our thematic indexes today, rising +13.3% on strong volume and renewed sector interest. Since inception on January 2, 2024, the index is now up +204.1%, placing it among the top-performing themes we track alongside Space and NextGen Tech & AI.

The backdrop is shifting in ways that matter. Late-stage clinical programs are advancing, regulatory pathways are becoming clearer, and investor attention is starting to follow the science. For retail investors who have been watching from the sidelines, 2026 is starting to look like the year this sector moves from fringe to mainstream conversation.

Here are the key names driving today’s move.

Compass Pathways (NASDAQ: CMPS)

Compass is the name most investors encounter first in this space, and for good reason. In February 2026, its COMP360 psilocybin therapy met the primary endpoint in a second Phase 3 trial for treatment-resistant depression. That is two successful pivotal studies, a threshold very few psychedelic programs have reached.

The company is now preparing for a potential NDA submission targeted for late 2026. If that filing advances, Compass could become the first psychedelic therapy to reach FDA review for a psychiatric indication. CMPS is trading around $6.00 to $6.40, up modestly today. Shares are up over 90% in the past 12 months, making it one of the stronger-performing names in the sector despite being slightly off year-to-date highs.

AtaiBeckley (NASDAQ: ATAI)

AtaiBeckley offers broader pipeline exposure following its combination with Beckley Psytech. The company is advancing BPL-003 into two Phase 3 trials for treatment-resistant depression, with enrollment expected to begin in Q2 2026. Recent Phase 2a data showed rapid and durable antidepressant effects, including in patients already on SSRIs — a finding that matters clinically because SSRI non-responders represent a large and underserved patient population.

The stock is trading in the $3.90 to $4.30 range, moving higher with the sector today, and is up over 90% in the past 12 months. With a cash runway extending into 2029 and multiple catalysts ahead, ATAI gives investors diversified exposure across the psychedelic pipeline rather than a single program bet.

Definium Therapeutics (NASDAQ: DFTX)

Definium, formerly MindMed, has rebranded and refocused around a late-stage psychiatry pipeline that is generating real momentum. Its lead candidate DT-120, an LSD-derived compound, has three Phase 3 readouts expected in 2026 across generalized anxiety disorder and major depressive disorder. That volume of late-stage data in a single year is unusual in any biotech category, let alone one as early as psychedelics.

DFTX is trading around $21.50 to $22.50 and contributed meaningfully to today’s index move. Shares are up over 65% year-to-date and more than 300% over the past 12 months. With a cash runway into 2028 and multiple readouts on the calendar, Definium is one of the more compelling risk-reward setups in the sector for investors who follow clinical-stage biotech.

GH Research (NASDAQ: GHRS)

GH Research is taking a different approach. The company is focused on inhaled 5-MeO-DMT, a fast-acting compound with a distinct mechanism from psilocybin or LSD derivatives. Its lead candidate GH001 completed a successful Phase 2b trial in treatment-resistant depression, with results published in JAMA Psychiatry. The FDA lifted a prior clinical hold earlier this year, clearing the path for a global Phase 3 program expected to begin in 2026.

Shares are trading in the $16.50 to $17.00 range, moving with the broader sector, and are up over 30% year-to-date and more than 100% over the past 12 months. A strong balance sheet and upcoming Phase 3 activity make GHRS a name worth holding on the watchlist as the program progresses.

Today’s move reflects something broader than a single-day catalyst. Multiple Phase 3 programs are running simultaneously, potential regulatory filings are on the horizon, and the clinical conversation around psychedelic-assisted therapies is maturing faster than most expected even two years ago.

This sector has been volatile, and that will not change. But the underlying progress is becoming harder to dismiss. For investors following the space, 2026 is shaping up to be a defining year — one where the data either validates the thesis or clarifies where the gaps remain.

Either way, it is worth paying attention.